TITLE

The Emerging Health Benefits of Coffee with an Emphasis on Type 2 Diabetes and Cardiovascular Disease

AUTHOR(S)
Bidel, Siamak; Tuomilehto, Jaakko
PUB. DATE
September 2013
SOURCE
European Endocrinology;Autumn2013, Vol. 9 Issue 2, p99
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Debate persists whether coffee is beneficial or problematic for human health, coffee consumption has been associated with a decrease in risk of developing type 2 diabetes, and numerous epidemiological studies have demonstrated that healthy, habitual coffee drinkers are more protected from the risk of contracting diabetes than individuals who do not drink coffee. Coffee consumption has been associated with a reduced incidence of impaired glucose tolerance, hyperglycaemia and insulin sensitivity. Data suggest that several coffee components, such as chlorogenic acids, are involved in the health benefits of coffee. Various mechanisms for this protective effect have been proposed, including effects on in cretin release, liver glucose metabolism and insulin sensitivity. Epidemiobgical data support numerous other health benefits for coffee, including reduced cardiovascular disease (CvD), a protective effect against some neurodegenerative conditions, a favourable effect on liver function and a protective effect against certain cancers These associations are based mainly on observational studies and are currently insufficient to recommend coffee consumption as an interventional strategy for risk reduction in type 2 diabetes and other metabolic diseases. While excessive consumption can have adverse effects on some conditions, particularly in terms of sleep quality, these effects vary among individuals and most people do not have any symptoms from coffee drinking. Moderate coffee consumption is associated with no or little risk of severe diseases and may offer substantial health benefits. Thus, coffee is a safe, low-energy beverage and suitable for most adult people.
ACCESSION #
94783544

 

Related Articles

  • Insulin resistance syndrome and cardiovascular risk.  // CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1267 

    Presents a summary of article dealing with insulin resistance syndrome and cardiovascular risk.

  • Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: Results of a 3-year study Mohteshamzadeh, Mobin; Wilkinson, Robert; Thomas, Simon H.L. // American Journal of Hypertension;Apr2005, Vol. 18 Issue 4, p452 

    Background: Insulin resistance is an independent risk factor for cardiovascular disease. The aim of this research was to establish the frequency of insulin resistance in a normoglycemic, hypertensive, male population to determine whether insulin resistance could be predicted by assessment of...

  • Vectocardiographic "Bites" as Possible Early Findings of Cardiac Involvement in Diabetic Patients Without Clinical Evidence of Heart Disease. Giampietro, Ottavio; Santoro, Gino; Rossi, Marco; Luche, Alessandro Dalle; Giusti, Costantino; Navalesi, Renzo // Angiology;Oct1982, Vol. 33 Issue 10, p668 

    We performed a standard vectocardiogram (VCG) in 87 diabetics, aged 20-77 years, orally- or insulin-treated, and in 41 normal subjects. None had cardiac history or symptoms. Among diabetics, 31 had no vectocardiographic abnormalities, 23 had various VCG changes, 33 showed electrical "bites'' of...

  • Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. Bouchard, Luigi; Faucher, Geneviève; Tchernof, André; Deshaies, Yves; Lebel, Stéfane; Hould, Frédéric-Simon; Marceau, Picard; Vohl, Marie-Claude // Acta Diabetologica;Mar2009, Vol. 46 Issue 1, p13 

    The incretin system has been shown to stimulate insulin secretion in a glucose dependent manner and currently fosters considerable hope for the treatment of diabetes. Recently, we have shown that the dipeptidylpeptidase-4 ( DPP4) gene, which is responsible for incretin inactivation, was...

  • Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management. OKADA, SADANORI; MORIMOTO, TAKESHI; OGAWA, HISAO; KANAUCHI, MASAO; NAKAYAMA, MASAFUMI; UEMURA, SHIRO; DOI, NAOFUMI; JINNOUCHI, HIDEAKI; WAKI, MASAKO; SOEJIMA, HIROFUMI; SAKUMA, MIO; SAITO, YOSHIHIKO // Diabetes Care;Jun2011, Vol. 34 Issue 6, p1277 

    OBJECTIVE--Recent reports showed that low-dose aspirin was ineffective in the primary prevention of cardiovascular events in diabetic patients overall. We hypothesized that low-dose aspirin would be beneficial in patients receiving insulin therapy, as a high-risk group. RESEARCH DESIGN AND...

  • Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases. Schultz, Olaf; Oberhauser, Frank; Saech, Jasemine; Rubbert-Roth, Andrea; Hahn, Moritz; Krone, Wilhelm; Laudes, Matthias // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been found to be increased in type 2 diabetic subjects. However, it still remains unclear if these elevated IL-6 levels are co-incidental or if this cytokine is causally related to the development of insulin resistance and...

  • Achieving Glycemic Goals with Vildagliptin. Pratley, R. E.; Schweizer, A.; Couturier, A.; Dejager, S. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA134 

    The ADA recommends a target A1C <7.0% to minimize risk of microvascular complications in patients (pts) with type 2 diabetes (T2DM), but a minority achieve this goal. Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control by increasing both α- and β-cell...

  • Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Juhl, Claus B.; Porksen, Niels; Hollingdal, Malene; Sturis, Jeppe; Pincus, Steven; Veldhuis, Johannes D.; Dejgaard, Anders; Schmitz, Ole; Juhl, C B; Pørksen, N; Hollingdal, M; Sturis, J; Pincus, S; Veldhuis, J D; Dejgaard, A; Schmitz, O // Diabetes Care;May2000, Vol. 23 Issue 5, p675 

    Objective: Repaglinide is a new oral hypoglycemic agent that acts as a prandial glucose regulator proposed for the treatment of type 2 diabetes by stimulating insulin secretion. The aim of this study was to explore actions of repaglinide on the rapid pulsatile insulin release by...

  • Type 2 Diabetes As An Inflammatory Cardiovascular Disorder. Ziegler, D. // Current Molecular Medicine;May2005, Vol. 5 Issue 3, p309 

    Type 2 diabetes carries a 2-6-fold increased risk of cardiovascular disease (CVD) and death. Indeed, the risk of major cardiovascular events in Type 2 diabetic patients without history of coronary heart disease (CHD) is equivalent to that observed in non-diabetic subjects with CHD. However,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics